Currency In USD
| Previous Close | 6.73 |
| Open | 6.84 |
| Day High | 6.86 |
| Day Low | 6.26 |
| 52-Week High | 31.35 |
| 52-Week Low | 4.39 |
| Volume | 1.43M |
| Average Volume | 2.67M |
| Market Cap | 825.8M |
| PE | -1.63 |
| EPS | -3.92 |
| Moving Average 50 Days | 9.86 |
| Moving Average 200 Days | 21.42 |
| Change | -0.35 |
Alumis to Present at the Leerink Partners Global Healthcare Conference
GlobeNewswire Inc.
Mar 02, 2026 1:05 PM GMT
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler,
Alumis to Participate in Upcoming February Investor Conferences
GlobeNewswire Inc.
Feb 05, 2026 1:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company wil
Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire Inc.
Jan 09, 2026 9:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the clos